Retinal implant technology has been advancing at a brisk pace in the European Union. Tiny devices that can be surgically implanted into the eyes of patients suffering from degenerative eye disorders is now clinically available, meaning people with the cash to spare (upwards of $100,000) can afford a miracle.
Two companies in particular are itching to make their products available far and wide. California based Second Sight and Germany’s Retina Implant AG have two distinct sight restoration systems that push the boundaries of high tech.
Here’s a detailed glimpse into Second Sight’s Argus II:
“With the Argus II system, a camera mounted on a pair of glasses captures images, and corresponding signals are fed wirelessly to chip implanted near the retina. These signals are sent to an array of implanted electrodes that stimulate retinal cells, producing light in the patient’s field of view. The process works for people with retinitis pigmentosa because the disease damages only the light-sensing photoreceptors, leaving the remaining retinal cells healthy.”
For the complete skinny read the full article by opening the link down below.